InsidersTradesSigma
Globus Medical INC Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Globus Medical INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Globus Medical INC has published 57 public disclosures. Market capitalisation: €10.4bn. The latest transaction was filed on 9 June 2026 (Levée d'options). Among the most active insiders: Davidar David D. Every trade is openly available.
57
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€11m
14 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Globus Medical INC Buy (bullish), based on 12 analysts. Average price target: US$107.42.
37Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 3,511 of 26,182 companies
71.0
score / 100
Value59
Quality83
FCF yld5.6%
Earn yld5.2%
EV/EBITDA12.9x
ROE13%
Gross mgn67%
Net mgn18%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 June 2026
Declarations57 total
25,000 shares@ US$26.270.0052% mcap5.9% of flowClass A Common StockSEC:0001193125-26-263997:0
25,000 shares@ US$80.76290.016% mcap18.3% of flowClass A Common StockSEC:0001193125-26-263997:1
8,000 shares@ US$81.00Class A Common StockSEC:0001193125-25-274288:0
10,000 shares@ US$58.4633.6% of flowClass A Common StockSEC:0001193125-25-205135:0
7,500 shares@ US$78.6857.9% of flowClass A Common StockSEC:0000950170-25-032220:0
5,833 shares@ US$49.6510.1% of flowClass A Common StockSEC:0000950170-25-005353:0
2,500 shares@ US$24.218.9% of flowClass A Common StockSEC:0000950170-24-133260:0
13,278 shares@ US$65.0546.9% of flowClass A Common StockSEC:0000950170-24-130597:0
50,000 shares@ US$43.7741.9% of flowClass A Common StockSEC:0000950170-24-130588:0
13,234 shares@ US$85.0014.8% of flowClass A Common StockSEC:0000950170-24-130603:0
26,042 shares@ US$24.10100.0% of flowClass A Common StockSEC:0000950170-24-129270:0
30,000 shares@ US$26.2714.6% of flowClass A Common StockSEC:0000950170-24-124113:0
5,000 shares@ US$24.2117.2% of flowClass A Common StockSEC:0000950170-24-124127:0
30,000 shares@ US$75.040128.8% of flowClass A Common StockSEC:0000950170-24-115615:0
7,500 shares@ US$25.8027.6% of flowClass A Common StockSEC:0000950170-24-115648:0
25,000 shares@ US$25.528.0% of flowClass A Common StockSEC:0000950170-24-107316:0
15,000 shares@ US$24.1033.3% of flowClass A Common StockSEC:0000950170-24-107319:0
1,000 shares@ US$70.0011.3% of flowClass A Common StockSEC:0000950170-24-083594:0
17,500 shares@ US$43.7740.7% of flowClass A Common StockSEC:0000950170-24-059787:0
20,000 shares@ US$65.0016.8% of flowClass A Common StockSEC:0000950170-24-057917:0
10,590 shares@ US$51.9988.7% of flowClass A Common StockSEC:0000950170-24-033817:0
7,500 shares@ US$24.9026.8% of flowClass A Common StockSEC:0000950170-24-026234:0
8,000 shares0Class A Common StockSEC:0000950170-24-007466:0
2,321 sharesClass A Common StockSEC:0001209191-23-048414:0
24,025 sharesClass A Common StockSEC:0001209191-23-048416:0
25 of 57 declarations
About Globus Medical INC
Globus Medical Inc. (NYSE: GMED) is a United States-listed medical technology company traded on the NYSE and headquartered in Audubon, Pennsylvania, United States. Founded in 2003, the company has built its business around musculoskeletal solutions, with an especially strong franchise in spine, and a broader presence in orthopedic trauma, joint reconstruction, regenerative biomaterials, and enabling technologies. Its model combines product design, manufacturing, commercialization, and clinical support, giving it a vertically integrated platform that is intended to serve surgeons and hospitals with procedure-based solutions rather than isolated products. ([investors.globusmedical.com](https://investors.globusmedical.com/?utm_source=openai)) From an equity analyst perspective, GMED is positioned in a structurally attractive market. Demand is supported by aging populations, the prevalence of spinal disorders, and the ongoing shift toward more efficient, less invasive procedures. Globus differentiates itself through a sustained innovation culture, a broad procedural portfolio, and a high-touch commercial model that aims to maintain close relationships with surgeons and care teams. The company describes itself as a single operating platform, which helps align research, development, manufacturing, education, and sales around unmet clinical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000156276225000026/gmed-20241231x10k.htm?utm_source=openai)) The company’s roots are in spine, where it initially established its brand and technical credibility, before expanding into adjacent musculoskeletal categories. In recent years, its strategic profile has become more ambitious through major transactions, most notably the NuVasive acquisition and the completion of the Nevro acquisition in 2025. Management has emphasized that integration remains a core operational priority, alongside a robust new-product pipeline and continued investment in commercial execution. ([investors.globusmedical.com](https://investors.globusmedical.com/news-events/press-releases?utm_source=openai)) Geographically, Globus derives the majority of its business from the United States, while also maintaining international activity through distributors and non-U.S. commercial channels. Recent disclosures point to solid momentum: the company reported 2025 full-year sales of $2.9389 billion, up 16.7%, with fourth-quarter growth driven by the core spine franchise and enabling technologies. In early 2026, management reiterated its focus on above-market growth, product innovation, and disciplined execution as it works through the integration of its acquisitions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-ye2025ex991.htm?utm_source=openai)) Overall, Globus Medical can be viewed as a growth-oriented healthcare technology company with a meaningful U.S. spine franchise, expanding procedural breadth, and a strategy centered on innovation, scale, and acquisition integration. ([investors.globusmedical.com](https://www.investors.globusmedical.com/news-events/press-releases?utm_source=openai))
